You searched for "tumour"
Robot assisted laparoscopic prostatectomy versus open retropubic prostatectomy – complication and readmission rates
Readmission rates in postoperative patients are an important health economic and clinical challenge faced in the modern NHS, with financial levies attached. In America since 2013, hospitals have been faced with ‘readmission penalties’ deducted from Medicare reimbursements. This was the...
Increasing PSA after negative prostate biopsy - solving the clinical puzzle
There are standard guidelines for first transrectal ultrasonography (TRUS) guided biopsy in a patient presenting with elevated prostate-specific antigen (PSA) or suspicious digital rectal examination (DRE) findings. Patients are generally warned before a TRUS biopsy in respect of a false...
Curing pure CIS with radical surgery: lessons learned
As carcinoma in situ (CIS) theoretically has no ability to invade or metastasise, performing radical cystectomy for CIS-only disease should be curative. In this single centre review over 37 years, 1964 patients undergoing cystectomy were analysed with 52 undergoing surgery...
Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high-risk UTUC
High-risk upper tract urothelial carcinoma (UTUC) has been associated with poor survival outcomes. The authors evaluated the role of neoadjuvant chemotherapy in high-risk cases prior to radical nephroureterectomy (RNU) in terms of pathological stage of the final surgical specimen. A...
Patients’ preferences for additional (cytoreductive) treatments to the prostate and metastasis in metastatic prostate cancer
Patients diagnosed with metastatic prostate cancer at first diagnosis or de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) have had reported increases in overall survival due to rapid advances and intensification of systemic therapy regimes beyond traditional androgen deprivation therapy...
Preoperative risk stratification of high-risk prostate cancer patients
High-risk prostate cancer (HRPCa) is associated with a significant risk of recurrence after radical treatment. While several classification systems exist, the D’Amico criteria – based on clinical T stage ≥T2c, prostate specific antigen (PSA) ≥20 ng/mL, or Gleason score (GS)...A viable alternative in prostate enucleation: PlasmaLEP
Lamidey Noury Medical is a French based factory with over 70 years of surgical expertise in electrosurgery. We proudly manufactured Plasma EDGE, a bipolar plasma resection system designed specifically for TURP and bladder tumour resection. We developed an innovative system...
Management dilemma for very high-risk non–muscle-invasive bladder cancer
The European Association of Urology (EAU) guidelines recommend upfront radical cystectomy (RC) for very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC). However, real-world adoption is limited, as most patients are reluctant to undergo immediate bladder removal. The EAU 2021 risk model...
